Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P01584
UPID:
IL1B_HUMAN
Alternative names:
Catabolin
Alternative UPACC:
P01584; Q53X59; Q53XX2; Q7M4S7; Q7RU01; Q96HE5; Q9UCT6
Background:
Interleukin-1 beta, also known as Catabolin, is a potent pro-inflammatory cytokine critical in mediating immune response. It plays a pivotal role in inducing fever, prostaglandin synthesis, and activating various immune cells. Additionally, it is involved in angiogenesis and inflammation downstream of pyroptosis, showcasing its versatility in immune modulation.
Therapeutic significance:
Understanding the role of Interleukin-1 beta could open doors to potential therapeutic strategies. Its involvement in a wide array of immune responses highlights its potential as a target for treating inflammatory diseases and modulating immune system activities.